Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMetolazone
Identification
- Name
- Metolazone
- Accession Number
- DB00524 (APRD01109)
- Type
- Small Molecule
- Groups
- Approved
- Description
A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. [PubChem]
- Structure
Structure for DB00524 (Metolazone)
- Synonyms
- 2-Methyl-3-O-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
- 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide
- 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-O-tolyl-6-quinazolinesulfonamide
- Metolazon
- Metolazona
- Métolazone
- Metolazonum
- External IDs
- SR 720-22
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Metolazone Tablet 5 mg/1 Oral H.j. Harkins Co., Inc. 2017-12-08 Not applicable US 
Zaroxolyn Tablet 5 mg/1 Oral Unither Pharmaceuticals 1973-11-27 2016-01-13 US Zaroxolyn Tablet 5 mg Oral Aventis Pharma Ltd. 1974-12-31 2003-07-22 Canada 
Zaroxolyn Tablet 2.5 mg/1 Oral Carilion Materials Management 1973-11-27 Not applicable US Zaroxolyn Tablet 2.5 mg Oral Sanofi Aventis 1974-12-31 Not applicable Canada Zaroxolyn Tab 10mg Tablet 10 mg Oral Rhone Poulenc Rorer 1974-12-31 1998-08-12 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Metolazone Tablet 5 mg/1 Oral Mc Kesson 2003-12-19 Not applicable US Metolazone Tablet 2.5 mg/1 Oral Ncs Health Care Of Ky, Inc Dba Vangard Labs 2010-01-18 Not applicable US Metolazone Tablet 2.5 mg/1 Oral Mylan Institutional 2005-04-15 Not applicable US Metolazone Tablet 5 mg/1 Oral Upstate Pharma, LLC 1973-11-27 Not applicable US 
Metolazone Tablet 5 mg/1 Oral Eon Labs, Inc. 2003-12-19 Not applicable US Metolazone Tablet 2.5 mg/1 Oral Cardinal Health 2011-01-14 2018-02-26 US Metolazone Tablet 10 mg/1 Oral Mylan Pharmaceuticals 2004-10-19 Not applicable US Metolazone Tablet 2.5 mg/1 Oral Avera Mc Kennan Hospital 2015-04-16 Not applicable US Metolazone Tablet 10 mg/1 Oral Eon Labs, Inc. 2003-12-19 Not applicable US Metolazone Tablet 2.5 mg/1 Oral Aphena Pharma Solutions Tennessee, Inc. 2004-01-06 Not applicable US - International/Other Brands
- Diulo / Diurem (Cipla) / Metadure (Micro Labs) / Metenix (IFET) / Metolaz (Navana) / Metoral (Dr. Reddy's) / Metoz (Centaur) / Metozone (Ying Yuan) / Mykrox (Celltech) / Pavedal (Pharma Investi) / Zaroxolyn / Zytanix (Zydus)
- Categories
- Amides
- Antihypertensive Agents
- Cardiovascular Agents
- Diuretics
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Hyperglycemia-Associated Agents
- Hypotensive Agents
- Membrane Transport Modulators
- Natriuretic Agents
- Quinazolines
- Quinazolinones
- Sodium Chloride Symporter Inhibitors
- Sulfonamides
- Sulfones
- Sulfur Compounds
- Thiazide-like Diuretic
- UNII
- TZ7V40X7VX
- CAS number
- 17560-51-9
- Weight
- Average: 365.835
Monoisotopic: 365.06008979 - Chemical Formula
- C16H16ClN3O3S
- InChI Key
- AQCHWTWZEMGIFD-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
- IUPAC Name
- 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
- SMILES
- CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O
Pharmacology
- Indication
For the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.
- Structured Indications
- Pharmacodynamics
Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.
- Mechanism of action
The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. The antihypertensive mechanism of action of metolazone is not fully understood but is presumed to be related to its saluretic and diuretic properties.
Target Actions Organism ASolute carrier family 12 member 3 inhibitorHuman - Absorption
Peak blood levels are obtained within 2 to 4 hours of oral administration. The rate and extent of absorption are formulation dependent.
- Volume of distribution
- Not Available
- Protein binding
50-70% bound to erythrocytes, up to 33% bound to plasma proteins, 2-5% of the drug in circulation is unbound
- Metabolism
Not substantially metabolized. 70-95% is excreted unchanged in urine via glomerular filtration and active tubular secretion. Undergoes enterohepatic recycling.
- Route of elimination
Most of the drug is excreted in the unconverted form in the urine.
- Half life
Approximately 14 hours.
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Metolazone Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The therapeutic efficacy of Metolazone can be decreased when used in combination with (4R)-limonene. Investigational 16-Bromoepiandrosterone 16-Bromoepiandrosterone may increase the hypokalemic activities of Metolazone. Investigational 19-norandrostenedione 19-norandrostenedione may increase the hypokalemic activities of Metolazone. Experimental, Illicit 1alpha-Hydroxyvitamin D5 The risk or severity of hyperkalemia can be increased when 1alpha-Hydroxyvitamin D5 is combined with Metolazone. Investigational 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Metolazone. Investigational 5-androstenedione 5-androstenedione may increase the hypokalemic activities of Metolazone. Experimental, Illicit 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metolazone. Experimental Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Metolazone. Approved, Investigational Acebutolol Metolazone may increase the hypotensive activities of Acebutolol. Approved, Investigational Aceclofenac The therapeutic efficacy of Metolazone can be decreased when used in combination with Aceclofenac. Approved, Investigational Acemetacin The therapeutic efficacy of Metolazone can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Metolazone. Approved, Investigational, Withdrawn Acetyldigitoxin The risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigitoxin. Approved Acetyldigoxin The risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigoxin. Experimental Acetylsalicylic acid The therapeutic efficacy of Metolazone can be decreased when used in combination with Acetylsalicylic acid. Approved, Vet Approved Aclidinium The serum concentration of Metolazone can be increased when it is combined with Aclidinium. Approved Adapalene The therapeutic efficacy of Metolazone can be decreased when used in combination with Adapalene. Approved AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Metolazone. Experimental, Investigational Alaproclate Alaproclate may increase the hyponatremic activities of Metolazone. Experimental Alclofenac The therapeutic efficacy of Metolazone can be decreased when used in combination with Alclofenac. Approved, Withdrawn Alclometasone Alclometasone may increase the hypokalemic activities of Metolazone. Approved Alcuronium The serum concentration of Metolazone can be increased when it is combined with Alcuronium. Experimental Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone. Approved Aldosterone Aldosterone may increase the hypokalemic activities of Metolazone. Experimental, Investigational Alfacalcidol The risk or severity of hyperkalemia can be increased when Alfacalcidol is combined with Metolazone. Approved, Nutraceutical Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Metolazone. Approved, Illicit Alfuzosin Alfuzosin may increase the hypotensive activities of Metolazone. Approved, Investigational Aliskiren Metolazone may increase the hypotensive activities of Aliskiren. Approved, Investigational Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Metolazone. Investigational Allopurinol The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Metolazone. Approved Alminoprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Alminoprofen. Experimental Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Metolazone. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Metolazone. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Alphaprodine is combined with Metolazone. Illicit Alprenolol Metolazone may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Ambrisentan Metolazone may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amcinonide Amcinonide may increase the hypokalemic activities of Metolazone. Approved Amifostine Metolazone may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Metolazone is combined with Amiloride. Approved Amiodarone The risk or severity of adverse effects can be increased when Amiodarone is combined with Metolazone. Approved, Investigational Amlodipine Amlodipine may increase the hypotensive activities of Metolazone. Approved Amobarbital Amobarbital may increase the orthostatic hypotensive activities of Metolazone. Approved, Illicit Amphetamine Amphetamine may increase the hypotensive activities of Metolazone. Approved, Illicit, Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Metolazone. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Metolazone is combined with Amyl Nitrite. Approved Andrographolide The therapeutic efficacy of Metolazone can be decreased when used in combination with Andrographolide. Investigational Androstenedione Androstenedione may increase the hypokalemic activities of Metolazone. Experimental, Illicit Anecortave Anecortave may increase the hypokalemic activities of Metolazone. Investigational anecortave acetate anecortave acetate may increase the hypokalemic activities of Metolazone. Investigational Anisodamine The therapeutic efficacy of Metolazone can be decreased when used in combination with Anisodamine. Investigational Anisotropine Methylbromide The serum concentration of Metolazone can be increased when it is combined with Anisotropine Methylbromide. Approved Antipyrine The therapeutic efficacy of Metolazone can be decreased when used in combination with Antipyrine. Approved, Investigational Apocynin The therapeutic efficacy of Metolazone can be decreased when used in combination with Apocynin. Investigational Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Metolazone. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Metolazone is combined with Apraclonidine. Approved Apremilast The therapeutic efficacy of Metolazone can be decreased when used in combination with Apremilast. Approved, Investigational Arbutamine Arbutamine may increase the hypokalemic activities of Metolazone. Approved Arformoterol Arformoterol may increase the hypokalemic activities of Metolazone. Approved, Investigational Aripiprazole Aripiprazole may increase the hypotensive activities of Metolazone. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Metolazone. Investigational Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Metolazone. Approved, Investigational Atamestane Atamestane may increase the hypokalemic activities of Metolazone. Investigational Atenolol Atenolol may increase the hypotensive activities of Metolazone. Approved Atracurium The serum concentration of Metolazone can be increased when it is combined with Atracurium. Approved, Experimental, Investigational Atracurium besylate The serum concentration of Metolazone can be increased when it is combined with Atracurium besylate. Approved Atropine The serum concentration of Metolazone can be increased when it is combined with Atropine. Approved, Vet Approved Avanafil Avanafil may increase the antihypertensive activities of Metolazone. Approved Azapropazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone. Withdrawn Azelastine The therapeutic efficacy of Metolazone can be decreased when used in combination with Azelastine. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil. Approved, Investigational Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Metolazone. Investigational Balsalazide The therapeutic efficacy of Metolazone can be decreased when used in combination with Balsalazide. Approved, Investigational Bambuterol Bambuterol may increase the hypokalemic activities of Metolazone. Approved, Investigational Barbexaclone Barbexaclone may increase the orthostatic hypotensive activities of Metolazone. Experimental Barbital Barbital may increase the orthostatic hypotensive activities of Metolazone. Illicit Barnidipine Metolazone may increase the antihypertensive activities of Barnidipine. Approved Beclomethasone dipropionate Beclomethasone dipropionate may increase the hypokalemic activities of Metolazone. Approved, Investigational Becocalcidiol The risk or severity of hyperkalemia can be increased when Becocalcidiol is combined with Metolazone. Investigational Bempedoic acid The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Metolazone. Investigational Benactyzine The serum concentration of Metolazone can be increased when it is combined with Benactyzine. Withdrawn Benazepril The risk or severity of hypotension can be increased when Metolazone is combined with Benazepril. Approved, Investigational Bendazac The therapeutic efficacy of Metolazone can be decreased when used in combination with Bendazac. Experimental Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Metolazone. Approved Benmoxin Benmoxin may increase the hypotensive activities of Metolazone. Withdrawn Benorilate The therapeutic efficacy of Metolazone can be decreased when used in combination with Benorilate. Experimental Benoxaprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Benoxaprofen. Withdrawn Benzatropine The serum concentration of Metolazone can be increased when it is combined with Benzatropine. Approved Benzydamine The therapeutic efficacy of Metolazone can be decreased when used in combination with Benzydamine. Approved Bepridil Metolazone may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betamethasone Betamethasone may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Betaxolol Betaxolol may increase the hypotensive activities of Metolazone. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Metolazone. Approved Bevonium The therapeutic efficacy of Metolazone can be decreased when used in combination with Bevonium. Experimental Bezitramide The risk or severity of adverse effects can be increased when Bezitramide is combined with Metolazone. Experimental, Illicit, Withdrawn Bietaserpine Bietaserpine may increase the hypotensive activities of Metolazone. Experimental Bimatoprost Metolazone may increase the hypotensive activities of Bimatoprost. Approved, Investigational Biperiden The serum concentration of Metolazone can be increased when it is combined with Biperiden. Approved, Investigational Bisoprolol Metolazone may increase the hypotensive activities of Bisoprolol. Approved Bornaprine The serum concentration of Metolazone can be increased when it is combined with Bornaprine. Experimental Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Metolazone. Approved, Investigational Bosentan Bosentan may increase the hypotensive activities of Metolazone. Approved, Investigational BQ-123 Metolazone may increase the hypotensive activities of BQ-123. Investigational Bretylium Metolazone may increase the hypotensive activities of Bretylium. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Metolazone. Approved Brofaromine Brofaromine may increase the hypotensive activities of Metolazone. Experimental Bromfenac The therapeutic efficacy of Metolazone can be decreased when used in combination with Bromfenac. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Metolazone. Approved, Investigational Bucillamine The therapeutic efficacy of Metolazone can be decreased when used in combination with Bucillamine. Investigational Budesonide Budesonide may increase the hypokalemic activities of Metolazone. Approved Bufexamac The therapeutic efficacy of Metolazone can be decreased when used in combination with Bufexamac. Approved, Experimental Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Metolazone. Investigational, Withdrawn Bumadizone The therapeutic efficacy of Metolazone can be decreased when used in combination with Bumadizone. Experimental Bumetanide The risk or severity of adverse effects can be increased when Metolazone is combined with Bumetanide. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Metolazone. Approved, Investigational Bupranolol Metolazone may increase the hypotensive activities of Bupranolol. Approved Buprenorphine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone. Approved, Illicit, Investigational, Vet Approved Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Metolazone. Approved, Illicit, Vet Approved Butylscopolamine The serum concentration of Metolazone can be increased when it is combined with Butylscopolamine. Approved, Investigational, Vet Approved Cadralazine Cadralazine may increase the hypotensive activities of Metolazone. Experimental Cafedrine Metolazone may increase the hypotensive activities of Cafedrine. Investigational Calcidiol The risk or severity of hyperkalemia can be increased when Calcidiol is combined with Metolazone. Approved, Nutraceutical Calcipotriol The risk or severity of hyperkalemia can be increased when Calcipotriol is combined with Metolazone. Approved Calcitriol The risk or severity of hyperkalemia can be increased when Calcitriol is combined with Metolazone. Approved, Nutraceutical Calcium Acetate Metolazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level. Approved, Investigational Calcium Chloride Metolazone may decrease the excretion rate of Calcium Chloride which could result in a higher serum level. Approved Calcium Citrate Metolazone may decrease the excretion rate of Calcium Citrate which could result in a higher serum level. Approved Calcium glubionate Metolazone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level. Approved Calcium Gluceptate Metolazone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level. Approved Calcium gluconate Metolazone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level. Approved, Vet Approved Calcium lactate Metolazone may decrease the excretion rate of Calcium lactate which could result in a higher serum level. Approved, Experimental, Investigational, Vet Approved Calcium lactate gluconate Metolazone may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level. Experimental Calcium levulinate Metolazone may decrease the excretion rate of Calcium levulinate which could result in a higher serum level. Approved, Experimental Calcium pangamate Metolazone may decrease the excretion rate of Calcium pangamate which could result in a higher serum level. Experimental Calcium Phosphate Metolazone may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level. Approved Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone. Approved Candesartan Metolazone may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Metolazone. Approved Candoxatril The risk or severity of hypotension can be increased when Metolazone is combined with Candoxatril. Experimental Captopril The risk or severity of hypotension can be increased when Metolazone is combined with Captopril. Approved Carbamazepine The risk or severity of adverse effects can be increased when Metolazone is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The therapeutic efficacy of Metolazone can be decreased when used in combination with Carbaspirin calcium. Experimental, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Metolazone. Approved, Investigational Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Metolazone. Experimental Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Metolazone. Illicit, Investigational, Vet Approved Caroxazone Caroxazone may increase the hypotensive activities of Metolazone. Withdrawn Carprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Carprofen. Approved, Vet Approved, Withdrawn Carteolol Carteolol may increase the hypotensive activities of Metolazone. Approved Carvedilol Metolazone may increase the hypotensive activities of Carvedilol. Approved, Investigational Casein Metolazone may decrease the excretion rate of Casein which could result in a higher serum level. Approved Castanospermine The therapeutic efficacy of Metolazone can be decreased when used in combination with Castanospermine. Experimental Celecoxib The therapeutic efficacy of Metolazone can be decreased when used in combination with Celecoxib. Approved, Investigational Celiprolol Celiprolol may increase the hypokalemic activities of Metolazone. Approved, Investigational Chloroquine The therapeutic efficacy of Metolazone can be decreased when used in combination with Chloroquine. Approved, Investigational, Vet Approved Chlorothiazide Metolazone may increase the hypotensive activities of Chlorothiazide. Approved, Vet Approved Chlorphenoxamine The serum concentration of Metolazone can be increased when it is combined with Chlorphenoxamine. Withdrawn Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metolazone. Approved, Investigational, Vet Approved Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Metolazone. Approved, Investigational Chlorthalidone Chlorthalidone may increase the hypotensive activities of Metolazone. Approved Cholecalciferol The risk or severity of hyperkalemia can be increased when Cholecalciferol is combined with Metolazone. Approved, Nutraceutical Cholestyramine Cholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The therapeutic efficacy of Metolazone can be decreased when used in combination with Choline magnesium trisalicylate. Approved Ciclesonide Ciclesonide may increase the hypokalemic activities of Metolazone. Approved, Investigational Cicletanine Metolazone may increase the hypotensive activities of Cicletanine. Investigational Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Metolazone. Experimental Cilazapril The risk or severity of hypotension can be increased when Metolazone is combined with Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Metolazone. Approved, Investigational Citalopram Citalopram may increase the hyponatremic activities of Metolazone. Approved Clenbuterol Clenbuterol may increase the hypokalemic activities of Metolazone. Approved, Investigational, Vet Approved Clevidipine The risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine. Approved, Investigational Clobetasol Clobetasol may increase the hypokalemic activities of Metolazone. Approved, Investigational Clobetasol propionate Clobetasol propionate may increase the hypokalemic activities of Metolazone. Approved Clobetasone Clobetasone may increase the hypokalemic activities of Metolazone. Approved Clocortolone Clocortolone may increase the hypokalemic activities of Metolazone. Approved Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Metolazone. Approved, Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Metolazone. Approved, Investigational, Vet Approved Clonidine Clonidine may increase the hypotensive activities of Metolazone. Approved Clonixin The therapeutic efficacy of Metolazone can be decreased when used in combination with Clonixin. Approved Cloranolol Metolazone may increase the hypotensive activities of Cloranolol. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Metolazone. Approved Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Metolazone. Approved, Illicit Colesevelam Colesevelam can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conivaptan The risk or severity of adverse effects can be increased when Conivaptan is combined with Metolazone. Approved, Investigational Cortexolone 17α-propionate Cortexolone 17α-propionate may increase the hypokalemic activities of Metolazone. Investigational Corticosterone Corticosterone may increase the hypokalemic activities of Metolazone. Experimental Cortisone acetate Cortisone acetate may increase the hypokalemic activities of Metolazone. Approved, Investigational Cryptenamine Metolazone may increase the hypotensive activities of Cryptenamine. Approved Curcumin The therapeutic efficacy of Metolazone can be decreased when used in combination with Curcumin. Approved, Investigational Cyclopenthiazide Metolazone may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclopentolate The serum concentration of Metolazone can be increased when it is combined with Cyclopentolate. Approved Cyclophosphamide The risk or severity of severe leukopenia can be increased when Metolazone is combined with Cyclophosphamide. Approved, Investigational Cyclothiazide Metolazone may increase the hypotensive activities of Cyclothiazide. Approved Cymarin The risk or severity of adverse effects can be increased when Metolazone is combined with Cymarin. Experimental Dapagliflozin The risk or severity of adverse effects can be increased when Metolazone is combined with Dapagliflozin. Approved Dapoxetine Dapoxetine may increase the hyponatremic activities of Metolazone. Investigational Darifenacin The serum concentration of Metolazone can be increased when it is combined with Darifenacin. Approved, Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Metolazone. Approved, Investigational Deflazacort Deflazacort may increase the hypokalemic activities of Metolazone. Approved, Investigational Delapril The risk or severity of hypotension can be increased when Metolazone is combined with Delapril. Experimental Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Metolazone. Investigational Deserpidine Metolazone may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Metolazone. Approved Deslanoside The risk or severity of adverse effects can be increased when Metolazone is combined with Deslanoside. Approved Desloratadine The serum concentration of Metolazone can be increased when it is combined with Desloratadine. Approved, Investigational Desonide Desonide may increase the hypokalemic activities of Metolazone. Approved, Investigational Desoximetasone Desoximetasone may increase the hypokalemic activities of Metolazone. Approved Desoxycorticosterone acetate Desoxycorticosterone acetate may increase the hypokalemic activities of Metolazone. Approved Desoxycorticosterone Pivalate Desoxycorticosterone Pivalate may increase the hypokalemic activities of Metolazone. Experimental, Vet Approved Desvenlafaxine Desvenlafaxine may increase the hyponatremic activities of Metolazone. Approved, Investigational Dexamethasone Dexamethasone may increase the hypokalemic activities of Metolazone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Dexamethasone isonicotinate may increase the hypokalemic activities of Metolazone. Vet Approved Dexetimide The serum concentration of Metolazone can be increased when it is combined with Dexetimide. Withdrawn Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Metolazone. Approved, Investigational Dexmedetomidine The risk or severity of adverse effects can be increased when Metolazone is combined with Dexmedetomidine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Metolazone. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metolazone. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Metolazone. Approved, Investigational Diazoxide The risk or severity of adverse effects can be increased when Metolazone is combined with Diazoxide. Approved Diclofenac The therapeutic efficacy of Metolazone can be decreased when used in combination with Diclofenac. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Metolazone is combined with Diclofenamide. Approved, Investigational Dicyclomine The serum concentration of Metolazone can be increased when it is combined with Dicyclomine. Approved Diethylnorspermine Metolazone may increase the hypotensive activities of Diethylnorspermine. Investigational Difenpiramide The therapeutic efficacy of Metolazone can be decreased when used in combination with Difenpiramide. Experimental Diflorasone Diflorasone may increase the hypokalemic activities of Metolazone. Approved Diflunisal The therapeutic efficacy of Metolazone can be decreased when used in combination with Diflunisal. Approved, Investigational Difluocortolone Difluocortolone may increase the hypokalemic activities of Metolazone. Approved, Investigational, Withdrawn Difluprednate Difluprednate may increase the hypokalemic activities of Metolazone. Approved Digitoxin The risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin. Approved, Investigational Digoxin The risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin. Approved Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin Immune Fab (Ovine). Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Metolazone. Approved, Investigational Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metolazone. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metolazone. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metolazone. Experimental, Illicit Dihydrotachysterol The risk or severity of hyperkalemia can be increased when Dihydrotachysterol is combined with Metolazone. Approved Diltiazem Diltiazem may increase the hypotensive activities of Metolazone. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metolazone. Approved, Illicit Dipivefrin Dipivefrin may increase the hypokalemic activities of Metolazone. Approved Dipyridamole The risk or severity of adverse effects can be increased when Metolazone is combined with Dipyridamole. Approved Dobutamine Dobutamine may increase the hypokalemic activities of Metolazone. Approved Dofetilide Metolazone may increase the QTc-prolonging activities of Dofetilide. Approved, Investigational Dorzolamide Metolazone may increase the hypotensive activities of Dorzolamide. Approved Doxazosin Doxazosin may increase the hypotensive activities of Metolazone. Approved Doxercalciferol The risk or severity of hyperkalemia can be increased when Doxercalciferol is combined with Metolazone. Approved Doxofylline Doxofylline may increase the hypokalemic activities of Metolazone. Approved, Investigational DPDPE The risk or severity of adverse effects can be increased when DPDPE is combined with Metolazone. Experimental Droxicam The therapeutic efficacy of Metolazone can be decreased when used in combination with Droxicam. Withdrawn Droxidopa Droxidopa may increase the hypokalemic activities of Metolazone. Approved, Investigational Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Metolazone. Approved, Investigational Duloxetine Metolazone may increase the orthostatic hypotensive activities of Duloxetine. Approved Duvelisib The therapeutic efficacy of Metolazone can be decreased when used in combination with Duvelisib. Investigational E-6201 The therapeutic efficacy of Metolazone can be decreased when used in combination with E-6201. Investigational Efonidipine Metolazone may increase the hypotensive activities of Efonidipine. Approved, Investigational Eldecalcitol The risk or severity of hyperkalemia can be increased when Eldecalcitol is combined with Metolazone. Investigational Elocalcitol The risk or severity of hyperkalemia can be increased when Elocalcitol is combined with Metolazone. Investigational Emepronium The serum concentration of Metolazone can be increased when it is combined with Emepronium. Experimental Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Metolazone. Approved Enalapril The risk or severity of hypotension can be increased when Metolazone is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of hypotension can be increased when Metolazone is combined with Enalaprilat. Approved Endralazine Endralazine may increase the hypotensive activities of Metolazone. Experimental Epanolol Metolazone may increase the hypotensive activities of Epanolol. Experimental Ephedra Ephedra may increase the hypokalemic activities of Metolazone. Approved, Nutraceutical, Withdrawn Epinephrine Epinephrine may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Epirizole The therapeutic efficacy of Metolazone can be decreased when used in combination with Epirizole. Approved Eplerenone The risk or severity of adverse effects can be increased when Metolazone is combined with Eplerenone. Approved Epoprostenol Metolazone may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Metolazone may increase the hypotensive activities of Eprosartan. Approved Equilenin Equilenin may increase the hypokalemic activities of Metolazone. Experimental Equilin Equilin may increase the hypokalemic activities of Metolazone. Approved Ergocalciferol The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Metolazone. Approved, Nutraceutical Escitalopram Escitalopram may increase the hyponatremic activities of Metolazone. Approved, Investigational Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Metolazone. Approved Estrone Estrone may increase the hypokalemic activities of Metolazone. Approved Estrone sulfate Estrone sulfate may increase the hypokalemic activities of Metolazone. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid. Approved, Investigational Etanautine The serum concentration of Metolazone can be increased when it is combined with Etanautine. Experimental Etanercept The therapeutic efficacy of Metolazone can be decreased when used in combination with Etanercept. Approved, Investigational Ethanol Ethanol may increase the orthostatic hypotensive activities of Metolazone. Approved Ethenzamide The therapeutic efficacy of Metolazone can be decreased when used in combination with Ethenzamide. Experimental Ethopropazine The serum concentration of Metolazone can be increased when it is combined with Ethopropazine. Approved Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metolazone. Approved, Illicit Etodolac The therapeutic efficacy of Metolazone can be decreased when used in combination with Etodolac. Approved, Investigational, Vet Approved Etofenamate The therapeutic efficacy of Metolazone can be decreased when used in combination with Etofenamate. Approved, Investigational Etoperidone Etoperidone may increase the hyponatremic activities of Metolazone. Withdrawn Etoricoxib The therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib. Approved, Investigational Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Metolazone. Illicit, Vet Approved Etybenzatropine The serum concentration of Metolazone can be increased when it is combined with Etybenzatropine. Experimental Evening primrose oil The therapeutic efficacy of Metolazone can be decreased when used in combination with Evening primrose oil. Approved, Investigational Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Metolazone. Approved, Investigational Exisulind The therapeutic efficacy of Metolazone can be decreased when used in combination with Exisulind. Investigational Felbinac The therapeutic efficacy of Metolazone can be decreased when used in combination with Felbinac. Experimental Felodipine Metolazone may increase the hypotensive activities of Felodipine. Approved, Investigational Fenbufen The therapeutic efficacy of Metolazone can be decreased when used in combination with Fenbufen. Approved Fenoldopam Metolazone may increase the hypotensive activities of Fenoldopam. Approved Fenoprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Fenoprofen. Approved Fenoterol Fenoterol may increase the hypokalemic activities of Metolazone. Approved, Investigational Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Metolazone. Approved, Illicit, Investigational, Vet Approved Fentiazac The therapeutic efficacy of Metolazone can be decreased when used in combination with Fentiazac. Experimental Feprazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Feprazone. Experimental Ferulic acid The therapeutic efficacy of Metolazone can be decreased when used in combination with Ferulic acid. Experimental Fesoterodine The serum concentration of Metolazone can be increased when it is combined with Fesoterodine. Approved Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Metolazone. Approved, Investigational Floctafenine The therapeutic efficacy of Metolazone can be decreased when used in combination with Floctafenine. Approved, Withdrawn Fluasterone Fluasterone may increase the hypokalemic activities of Metolazone. Investigational Fludrocortisone Fludrocortisone may increase the hypokalemic activities of Metolazone. Approved, Investigational Flumethasone Flumethasone may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Flunisolide Flunisolide may increase the hypokalemic activities of Metolazone. Approved, Investigational Flunixin The therapeutic efficacy of Metolazone can be decreased when used in combination with Flunixin. Vet Approved Flunoxaprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Flunoxaprofen. Experimental Fluocinolone Acetonide Fluocinolone Acetonide may increase the hypokalemic activities of Metolazone. Approved, Investigational, Vet Approved Fluocinonide Fluocinonide may increase the hypokalemic activities of Metolazone. Approved, Investigational Fluocortolone Fluocortolone may increase the hypokalemic activities of Metolazone. Approved, Withdrawn Fluorometholone Fluorometholone may increase the hypokalemic activities of Metolazone. Approved, Investigational Fluoxetine Fluoxetine may increase the hyponatremic activities of Metolazone. Approved, Vet Approved Fluprednidene Fluprednidene may increase the hypokalemic activities of Metolazone. Approved, Withdrawn Fluprednisolone Fluprednisolone may increase the hypokalemic activities of Metolazone. Approved Flurandrenolide Flurandrenolide may increase the hypokalemic activities of Metolazone. Approved Flurbiprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Flurbiprofen. Approved, Investigational Fluticasone furoate Fluticasone furoate may increase the hypokalemic activities of Metolazone. Approved Fluticasone propionate Fluticasone propionate may increase the hypokalemic activities of Metolazone. Approved Fluvoxamine Fluvoxamine may increase the hyponatremic activities of Metolazone. Approved, Investigational Formestane Formestane may increase the hypokalemic activities of Metolazone. Approved, Investigational, Withdrawn Formoterol Formoterol may increase the hypokalemic activities of Metolazone. Approved, Investigational Fosinopril The risk or severity of hypotension can be increased when Metolazone is combined with Fosinopril. Approved Furazolidone Furazolidone may increase the hypotensive activities of Metolazone. Approved, Investigational, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Metolazone is combined with Furosemide. Approved, Vet Approved Gallamine The serum concentration of Metolazone can be increased when it is combined with Gallamine. Experimental Gallamine Triethiodide The serum concentration of Metolazone can be increased when it is combined with Gallamine Triethiodide. Approved Gitoformate The risk or severity of adverse effects can be increased when Metolazone is combined with Gitoformate. Experimental Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Metolazone. Investigational, Withdrawn Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Metolazone. Approved Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Metolazone. Approved Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Metolazone. Approved, Investigational Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Metolazone. Approved, Investigational Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Metolazone. Approved Glycopyrronium The serum concentration of Metolazone can be increased when it is combined with Glycopyrronium. Approved, Investigational, Vet Approved Guacetisal The therapeutic efficacy of Metolazone can be decreased when used in combination with Guacetisal. Experimental Guanabenz Metolazone may increase the hypotensive activities of Guanabenz. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Metolazone. Approved Guanazodine Metolazone may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Metolazone may increase the hypotensive activities of Guanethidine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Metolazone. Approved, Investigational Guanoclor Metolazone may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Metolazone may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Metolazone may increase the hypotensive activities of Guanoxan. Experimental Gusperimus The therapeutic efficacy of Gusperimus can be decreased when used in combination with Metolazone. Investigational Halcinonide Halcinonide may increase the hypokalemic activities of Metolazone. Approved, Investigational, Withdrawn Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Metolazone. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Metolazone. Experimental HE3286 HE3286 may increase the hypokalemic activities of Metolazone. Investigational Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Metolazone. Approved, Illicit, Investigational Hexamethonium The serum concentration of Metolazone can be increased when it is combined with Hexamethonium. Experimental Hexobarbital Hexobarbital may increase the orthostatic hypotensive activities of Metolazone. Approved Higenamine The therapeutic efficacy of Metolazone can be decreased when used in combination with Higenamine. Investigational Homatropine The serum concentration of Metolazone can be increased when it is combined with Homatropine. Approved Hydracarbazine Hydracarbazine may increase the hypotensive activities of Metolazone. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Metolazone. Approved Hydrochlorothiazide Metolazone may increase the hypotensive activities of Hydrochlorothiazide. Approved, Vet Approved Hydrocodone The risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone. Approved, Illicit Hydrocortisone Hydrocortisone may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Hydroflumethiazide Metolazone may increase the hypotensive activities of Hydroflumethiazide. Approved, Investigational Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone. Approved, Illicit Hyoscyamine The serum concentration of Metolazone can be increased when it is combined with Hyoscyamine. Approved Ibuprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuprofen. Approved Ibuproxam The therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuproxam. Withdrawn Icatibant The therapeutic efficacy of Metolazone can be decreased when used in combination with Icatibant. Approved, Investigational Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Metolazone. Approved, Investigational Imidapril The risk or severity of hypotension can be increased when Metolazone is combined with Imidapril. Investigational Imidazole salicylate The therapeutic efficacy of Metolazone can be decreased when used in combination with Imidazole salicylate. Experimental Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Metolazone. Approved Indacaterol Indacaterol may increase the hypokalemic activities of Metolazone. Approved Indalpine Indalpine may increase the hyponatremic activities of Metolazone. Investigational, Withdrawn Indapamide Metolazone may increase the hypotensive activities of Indapamide. Approved Indenolol Metolazone may increase the hypotensive activities of Indenolol. Withdrawn Indobufen The therapeutic efficacy of Metolazone can be decreased when used in combination with Indobufen. Investigational Indomethacin The therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin. Approved, Investigational Indoprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Indoprofen. Withdrawn Indoramin Indoramin may increase the hypotensive activities of Metolazone. Withdrawn Inecalcitol The risk or severity of hyperkalemia can be increased when Inecalcitol is combined with Metolazone. Experimental, Investigational Insulin Aspart The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Metolazone. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Metolazone. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Metolazone. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Metolazone. Approved Insulin Human The therapeutic efficacy of Insulin Human can be decreased when used in combination with Metolazone. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Metolazone. Approved Ipratropium bromide The serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide. Approved Iproclozide Iproclozide may increase the hypotensive activities of Metolazone. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Metolazone. Withdrawn Irbesartan Metolazone may increase the hypotensive activities of Irbesartan. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Metolazone. Approved Isoetarine Isoetarine may increase the hypokalemic activities of Metolazone. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Metolazone. Approved, Vet Approved Isoprenaline Isoprenaline may increase the hypokalemic activities of Metolazone. Approved, Investigational Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Mononitrate. Approved Isoxicam The therapeutic efficacy of Metolazone can be decreased when used in combination with Isoxicam. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Metolazone is combined with Isoxsuprine. Approved, Withdrawn Isradipine Isradipine may increase the hypotensive activities of Metolazone. Approved, Investigational Istaroxime Istaroxime may increase the hypokalemic activities of Metolazone. Investigational Ivabradine Metolazone may increase the arrhythmogenic activities of Ivabradine. Approved Kebuzone The therapeutic efficacy of Metolazone can be decreased when used in combination with Kebuzone. Experimental Ketanserin Ketanserin may increase the hypotensive activities of Metolazone. Investigational Ketobemidone The risk or severity of adverse effects can be increased when Ketobemidone is combined with Metolazone. Approved, Investigational Ketoprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Ketorolac The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketorolac. Approved Labetalol Metolazone may increase the hypotensive activities of Labetalol. Approved Lacidipine Metolazone may increase the hypotensive activities of Lacidipine. Approved, Investigational Lanatoside C The risk or severity of adverse effects can be increased when Metolazone is combined with Lanatoside C. Experimental Latanoprost Metolazone may increase the hypotensive activities of Latanoprost. Approved, Investigational Leflunomide The therapeutic efficacy of Metolazone can be decreased when used in combination with Leflunomide. Approved, Investigational Lercanidipine Metolazone may increase the hypotensive activities of Lercanidipine. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Metolazone is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Metolazone. Approved, Investigational Levodopa Metolazone may increase the orthostatic hypotensive activities of Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metolazone. Approved, Investigational Levomilnacipran Levomilnacipran may increase the hyponatremic activities of Metolazone. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Metolazone. Approved Levosalbutamol Levosalbutamol may increase the hypokalemic activities of Metolazone. Approved, Investigational Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Metolazone. Approved, Investigational Licorice Licorice may increase the hypokalemic activities of Metolazone. Approved Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone. Approved Linsidomine Metolazone may increase the hypotensive activities of Linsidomine. Experimental Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Metolazone. Approved Lisinopril The risk or severity of hypotension can be increased when Metolazone is combined with Lisinopril. Approved, Investigational Lisofylline The therapeutic efficacy of Metolazone can be decreased when used in combination with Lisofylline. Investigational Lithium Metolazone may decrease the excretion rate of Lithium which could result in a higher serum level. Approved Lofentanil The risk or severity of adverse effects can be increased when Lofentanil is combined with Metolazone. Illicit Lofexidine Metolazone may increase the hypotensive activities of Lofexidine. Approved, Investigational Lonazolac The therapeutic efficacy of Metolazone can be decreased when used in combination with Lonazolac. Experimental Lornoxicam The therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam. Approved, Investigational Losartan Metolazone may increase the hypotensive activities of Losartan. Approved Loteprednol Loteprednol may increase the hypokalemic activities of Metolazone. Approved Loxoprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Loxoprofen. Approved, Investigational Lumiracoxib The therapeutic efficacy of Metolazone can be decreased when used in combination with Lumiracoxib. Approved, Investigational Macitentan Metolazone may increase the hypotensive activities of Macitentan. Approved Magnesium salicylate The therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate. Approved Manidipine Metolazone may increase the hypotensive activities of Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol. Approved, Investigational Masoprocol The therapeutic efficacy of Metolazone can be decreased when used in combination with Masoprocol. Approved, Investigational Maxacalcitol The risk or severity of hyperkalemia can be increased when Maxacalcitol is combined with Metolazone. Approved, Investigational Mazaticol The serum concentration of Metolazone can be increased when it is combined with Mazaticol. Experimental ME-609 ME-609 may increase the hypokalemic activities of Metolazone. Investigational Mebanazine Mebanazine may increase the hypotensive activities of Metolazone. Withdrawn Mecamylamine The risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine. Approved, Investigational Meclofenamic acid The therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Medrysone Medrysone may increase the hypokalemic activities of Metolazone. Approved Mefenamic acid The therapeutic efficacy of Metolazone can be decreased when used in combination with Mefenamic acid. Approved Melengestrol Melengestrol may increase the hypokalemic activities of Metolazone. Vet Approved Meloxicam The therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam. Approved, Vet Approved Meptazinol The risk or severity of adverse effects can be increased when Meptazinol is combined with Metolazone. Experimental Mesalazine The therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine. Approved Metamizole The therapeutic efficacy of Metolazone can be decreased when used in combination with Metamizole. Approved, Investigational, Withdrawn Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Metolazone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Metolazone. Approved, Illicit Methantheline The serum concentration of Metolazone can be increased when it is combined with Methantheline. Approved, Investigational Methazolamide The risk or severity of adverse effects can be increased when Metolazone is combined with Methazolamide. Approved Methohexital Methohexital may increase the orthostatic hypotensive activities of Metolazone. Approved Methoserpidine Metolazone may increase the hypotensive activities of Methoserpidine. Experimental Methscopolamine The serum concentration of Metolazone can be increased when it is combined with Methscopolamine. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone. Approved Methyldopa Metolazone may increase the hypotensive activities of Methyldopa. Approved Methylene blue Methylene blue may increase the hypotensive activities of Metolazone. Approved, Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Metolazone. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the orthostatic hypotensive activities of Metolazone. Approved Methylprednisolone Methylprednisolone may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Methylscopolamine bromide The serum concentration of Metolazone can be increased when it is combined with Methylscopolamine bromide. Approved Metildigoxin The risk or severity of adverse effects can be increased when Metolazone is combined with Metildigoxin. Experimental Metipranolol Metolazone may increase the hypotensive activities of Metipranolol. Approved Metixene The serum concentration of Metolazone can be increased when it is combined with Metixene. Approved Metoprolol Metoprolol may increase the hypotensive activities of Metolazone. Approved, Investigational Metyrosine Metolazone may increase the hypotensive activities of Metyrosine. Approved Mibefradil Metolazone may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Metolazone. Approved Miglustat The therapeutic efficacy of Miglustat can be decreased when used in combination with Metolazone. Approved Milnacipran Milnacipran may increase the hyponatremic activities of Metolazone. Approved, Investigational Minaprine Minaprine may increase the hypotensive activities of Metolazone. Approved Minoxidil Minoxidil may increase the hypotensive activities of Metolazone. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Metolazone. Investigational Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Metolazone. Approved, Investigational Mizoribine The therapeutic efficacy of Metolazone can be decreased when used in combination with Mizoribine. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Metolazone. Approved, Investigational Moexipril The risk or severity of hypotension can be increased when Metolazone is combined with Moexipril. Approved Mofebutazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Mofebutazone. Experimental Molsidomine Molsidomine may increase the hypotensive activities of Metolazone. Approved, Investigational Mometasone Mometasone may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Metolazone. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Metolazone. Approved, Investigational Muzolimine Metolazone may increase the hypotensive activities of Muzolimine. Experimental Mycophenolate mofetil The therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolate mofetil. Approved, Investigational Mycophenolic acid The therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid. Approved Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Metolazone. Approved, Investigational Nabumetone The therapeutic efficacy of Metolazone can be decreased when used in combination with Nabumetone. Approved Nadolol Metolazone may increase the hypotensive activities of Nadolol. Approved Nafamostat The therapeutic efficacy of Metolazone can be decreased when used in combination with Nafamostat. Approved, Investigational Naftifine The therapeutic efficacy of Metolazone can be decreased when used in combination with Naftifine. Approved Naftopidil Metolazone may increase the hypotensive activities of Naftopidil. Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Metolazone. Approved Naproxen The therapeutic efficacy of Metolazone can be decreased when used in combination with Naproxen. Approved, Vet Approved Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Metolazone. Approved, Investigational NCX 1022 NCX 1022 may increase the hypokalemic activities of Metolazone. Investigational Nebivolol Metolazone may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone Nefazodone may increase the hyponatremic activities of Metolazone. Approved, Withdrawn Nepafenac The therapeutic efficacy of Metolazone can be decreased when used in combination with Nepafenac. Approved, Investigational Nesiritide The risk or severity of adverse effects can be increased when Metolazone is combined with Nesiritide. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Metolazone. Withdrawn Nicardipine Metolazone may increase the hypotensive activities of Nicardipine. Approved, Investigational Nicomorphine The risk or severity of adverse effects can be increased when Nicomorphine is combined with Metolazone. Experimental Nicorandil Nicorandil may increase the hypotensive activities of Metolazone. Approved, Investigational Nifedipine The risk or severity of adverse effects can be increased when Metolazone is combined with Nifedipine. Approved Nifenazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Nifenazone. Experimental Niflumic Acid The therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic Acid. Approved Niguldipine Metolazone may increase the hypotensive activities of Niguldipine. Experimental Nilvadipine Metolazone may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimesulide The therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide. Approved, Investigational, Withdrawn Nimodipine Nimodipine may increase the hypotensive activities of Metolazone. Approved, Investigational Nisoldipine Nisoldipine may increase the hypotensive activities of Metolazone. Approved Nitrendipine Metolazone may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Metolazone. Approved Nitroaspirin The therapeutic efficacy of Metolazone can be decreased when used in combination with Nitroaspirin. Investigational Nitroglycerin The risk or severity of adverse effects can be increased when Metolazone is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Metolazone. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Nitrous acid is combined with Metolazone. Approved, Investigational Norepinephrine Norepinephrine may increase the hypokalemic activities of Metolazone. Approved Normethadone The risk or severity of adverse effects can be increased when Normethadone is combined with Metolazone. Approved, Illicit Obinutuzumab Metolazone may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Metolazone. Withdrawn Oleandrin The risk or severity of adverse effects can be increased when Metolazone is combined with Oleandrin. Experimental, Investigational Oleoyl-estrone Oleoyl-estrone may increase the hypokalemic activities of Metolazone. Investigational Olmesartan Olmesartan may increase the hypotensive activities of Metolazone. Approved, Investigational Olodaterol Olodaterol may increase the hypokalemic activities of Metolazone. Approved Olopatadine The therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine. Approved Olsalazine The therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine. Approved Omapatrilat The risk or severity of hypotension can be increased when Metolazone is combined with Omapatrilat. Investigational Opium The risk or severity of adverse effects can be increased when Opium is combined with Metolazone. Approved, Illicit Orciprenaline Orciprenaline may increase the hypokalemic activities of Metolazone. Approved Orgotein The therapeutic efficacy of Metolazone can be decreased when used in combination with Orgotein. Vet Approved Orphenadrine The serum concentration of Metolazone can be increased when it is combined with Orphenadrine. Approved Otilonium The serum concentration of Metolazone can be increased when it is combined with Otilonium. Experimental, Investigational Ouabain The risk or severity of adverse effects can be increased when Metolazone is combined with Ouabain. Approved Oxaprozin The therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin. Approved Oxcarbazepine The risk or severity of hyponatremia can be increased when Metolazone is combined with Oxcarbazepine. Approved Oxitropium The serum concentration of Metolazone can be increased when it is combined with Oxitropium. Investigational Oxprenolol Metolazone may increase the hypotensive activities of Oxprenolol. Approved Oxybutynin The serum concentration of Metolazone can be increased when it is combined with Oxybutynin. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Metolazone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Metolazone. Approved, Investigational, Vet Approved Oxyphenbutazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone. Approved, Withdrawn Oxyphenonium The serum concentration of Metolazone can be increased when it is combined with Oxyphenonium. Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Metolazone. Approved, Vet Approved Pancuronium The serum concentration of Metolazone can be increased when it is combined with Pancuronium. Approved Papaverine The risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine. Approved, Investigational Paramethasone Paramethasone may increase the hypokalemic activities of Metolazone. Approved Parecoxib The therapeutic efficacy of Metolazone can be decreased when used in combination with Parecoxib. Approved Pargyline Pargyline may increase the hypotensive activities of Metolazone. Approved Paricalcitol The risk or severity of hyperkalemia can be increased when Paricalcitol is combined with Metolazone. Approved, Investigational Paroxetine Paroxetine may increase the hyponatremic activities of Metolazone. Approved, Investigational Parthenolide The therapeutic efficacy of Metolazone can be decreased when used in combination with Parthenolide. Approved, Investigational Penbutolol Metolazone may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone. Approved, Vet Approved Pentobarbital Pentobarbital may increase the orthostatic hypotensive activities of Metolazone. Approved, Investigational, Vet Approved Pentolinium The serum concentration of Metolazone can be increased when it is combined with Pentolinium. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Metolazone. Approved, Investigational Perindopril The risk or severity of hypotension can be increased when Metolazone is combined with Perindopril. Approved Peruvoside The risk or severity of adverse effects can be increased when Metolazone is combined with Peruvoside. Experimental Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Metolazone. Approved Phenazocine The risk or severity of adverse effects can be increased when Phenazocine is combined with Metolazone. Experimental Phenelzine Phenelzine may increase the hypotensive activities of Metolazone. Approved Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Metolazone. Approved, Investigational, Withdrawn Phenglutarimide The serum concentration of Metolazone can be increased when it is combined with Phenglutarimide. Experimental Pheniprazine Pheniprazine may increase the hypotensive activities of Metolazone. Withdrawn Phenobarbital Phenobarbital may increase the orthostatic hypotensive activities of Metolazone. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Phenoperidine is combined with Metolazone. Experimental Phenoxybenzamine Metolazone may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Metolazone. Withdrawn Phentolamine Metolazone may increase the hypotensive activities of Phentolamine. Approved Phenylbutazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Phenylbutazone. Approved, Vet Approved Phenylpropanolamine Phenylpropanolamine may increase the hypokalemic activities of Metolazone. Approved, Vet Approved, Withdrawn Pimecrolimus The therapeutic efficacy of Metolazone can be decreased when used in combination with Pimecrolimus. Approved, Investigational Pinacidil Pinacidil may increase the hypotensive activities of Metolazone. Approved Pindolol Metolazone may increase the hypotensive activities of Pindolol. Approved, Investigational Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Metolazone. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Pipamperone is combined with Metolazone. Approved, Investigational Pipecuronium The serum concentration of Metolazone can be increased when it is combined with Pipecuronium. Approved Pirbuterol Pirbuterol may increase the hypokalemic activities of Metolazone. Approved Pirenzepine The serum concentration of Metolazone can be increased when it is combined with Pirenzepine. Approved Pirfenidone The therapeutic efficacy of Metolazone can be decreased when used in combination with Pirfenidone. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Piritramide is combined with Metolazone. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Metolazone. Approved Piroxicam The therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam. Approved, Investigational Pirprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Pirprofen. Experimental Pivhydrazine Pivhydrazine may increase the hypotensive activities of Metolazone. Withdrawn Platelet Activating Factor Metolazone may increase the hypotensive activities of Platelet Activating Factor. Experimental Polythiazide Metolazone may increase the hypotensive activities of Polythiazide. Approved Pramipexole The risk or severity of adverse effects can be increased when Pramipexole is combined with Metolazone. Approved, Investigational Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Metolazone. Approved, Investigational Pranoprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Pranoprofen. Experimental, Investigational Prasterone Prasterone may increase the hypokalemic activities of Metolazone. Approved, Investigational, Nutraceutical Prasterone sulfate Prasterone sulfate may increase the hypokalemic activities of Metolazone. Investigational Prazosin Prazosin may increase the hypotensive activities of Metolazone. Approved Prednicarbate Prednicarbate may increase the hypokalemic activities of Metolazone. Approved, Investigational Prednisolone Prednisolone may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Prednisone Prednisone may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Pregnenolone Pregnenolone may increase the hypokalemic activities of Metolazone. Approved, Experimental, Investigational Primidone Primidone may increase the orthostatic hypotensive activities of Metolazone. Approved, Vet Approved Procarbazine Procarbazine may increase the hypotensive activities of Metolazone. Approved, Investigational Procaterol Procaterol may increase the hypokalemic activities of Metolazone. Approved, Investigational Procyclidine The serum concentration of Metolazone can be increased when it is combined with Procyclidine. Approved Proglumetacin The therapeutic efficacy of Metolazone can be decreased when used in combination with Proglumetacin. Experimental Propacetamol The therapeutic efficacy of Metolazone can be decreased when used in combination with Propacetamol. Approved, Investigational Propantheline The serum concentration of Metolazone can be increased when it is combined with Propantheline. Approved Propiverine The serum concentration of Metolazone can be increased when it is combined with Propiverine. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Metolazone. Approved, Investigational, Vet Approved Propranolol Metolazone may increase the hypotensive activities of Propranolol. Approved, Investigational Propyphenazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Propyphenazone. Experimental Proquazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Proquazone. Experimental Proscillaridin The risk or severity of adverse effects can be increased when Metolazone is combined with Proscillaridin. Experimental Protokylol Protokylol may increase the hypokalemic activities of Metolazone. Approved, Vet Approved PTC299 The therapeutic efficacy of Metolazone can be decreased when used in combination with PTC299. Investigational Quetiapine The risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine. Approved Quinapril The risk or severity of hypotension can be increased when Metolazone is combined with Quinapril. Approved, Investigational Quinidine The serum concentration of Metolazone can be increased when it is combined with Quinidine. Approved, Investigational Quinine Quinine may increase the hypotensive activities of Metolazone. Approved Racepinephrine Racepinephrine may increase the hypokalemic activities of Metolazone. Approved Ramipril The risk or severity of hypotension can be increased when Metolazone is combined with Ramipril. Approved Rasagiline Rasagiline may increase the hypotensive activities of Metolazone. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Metolazone. Approved Remikiren Remikiren may increase the hypotensive activities of Metolazone. Approved Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Metolazone. Approved, Investigational Rescinnamine The risk or severity of hypotension can be increased when Metolazone is combined with Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Metolazone. Approved, Investigational Resveratrol The therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol. Approved, Experimental, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Metolazone. Approved, Investigational Rimexolone Rimexolone may increase the hypokalemic activities of Metolazone. Approved Riociguat Metolazone may increase the hypotensive activities of Riociguat. Approved Risperidone Metolazone may increase the hypotensive activities of Risperidone. Approved, Investigational Ritodrine Ritodrine may increase the hypokalemic activities of Metolazone. Approved, Investigational Rituximab Metolazone may increase the hypotensive activities of Rituximab. Approved Rofecoxib The therapeutic efficacy of Metolazone can be decreased when used in combination with Rofecoxib. Approved, Investigational, Withdrawn Ropinirole The risk or severity of adverse effects can be increased when Ropinirole is combined with Metolazone. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Metolazone. Approved Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Metolazone. Approved, Investigational Rotigotine The risk or severity of adverse effects can be increased when Rotigotine is combined with Metolazone. Approved Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Metolazone. Approved Safrazine Safrazine may increase the hypotensive activities of Metolazone. Withdrawn Salbutamol Salbutamol may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Salicylamide The therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide. Approved Salicylic acid The therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylic acid. Approved, Investigational, Vet Approved Salmeterol Salmeterol may increase the hypokalemic activities of Metolazone. Approved Salsalate The therapeutic efficacy of Metolazone can be decreased when used in combination with Salsalate. Approved Saprisartan Metolazone may increase the hypotensive activities of Saprisartan. Experimental Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Metolazone. Approved Scopolamine The serum concentration of Metolazone can be increased when it is combined with Scopolamine. Approved, Investigational Secobarbital Secobarbital may increase the orthostatic hypotensive activities of Metolazone. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Metolazone. Approved, Investigational, Vet Approved Selexipag Metolazone may increase the hypotensive activities of Selexipag. Approved Semapimod The therapeutic efficacy of Metolazone can be decreased when used in combination with Semapimod. Investigational Seocalcitol The risk or severity of hyperkalemia can be increased when Seocalcitol is combined with Metolazone. Experimental, Investigational Seratrodast The therapeutic efficacy of Metolazone can be decreased when used in combination with Seratrodast. Approved Serrapeptase The therapeutic efficacy of Metolazone can be decreased when used in combination with Serrapeptase. Investigational Sertraline Sertraline may increase the hyponatremic activities of Metolazone. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Metolazone. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Metolazone. Approved, Investigational Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Metolazone. Approved, Investigational Sitaxentan Metolazone may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium phosphate Metolazone may increase the nephrotoxic activities of Sodium phosphate. Approved Solifenacin The serum concentration of Metolazone can be increased when it is combined with Solifenacin. Approved Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Metolazone. Investigational Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone. Approved Spirapril The risk or severity of hypotension can be increased when Metolazone is combined with Spirapril. Approved Spironolactone The risk or severity of adverse effects can be increased when Spironolactone is combined with Metolazone. Approved SRT501 The therapeutic efficacy of Metolazone can be decreased when used in combination with SRT501. Investigational Streptokinase The risk or severity of adverse effects can be increased when Streptokinase is combined with Metolazone. Approved, Investigational Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone. Approved, Investigational Sulfasalazine The therapeutic efficacy of Metolazone can be decreased when used in combination with Sulfasalazine. Approved Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Metolazone. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride. Approved, Investigational Suprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Suprofen. Approved, Withdrawn Suxibuzone The therapeutic efficacy of Metolazone can be decreased when used in combination with Suxibuzone. Experimental Tacalcitol The risk or severity of hyperkalemia can be increased when Tacalcitol is combined with Metolazone. Experimental, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Metolazone. Approved, Investigational Talinolol Metolazone may increase the hypotensive activities of Talinolol. Investigational Tamsulosin The risk or severity of adverse effects can be increased when Tamsulosin is combined with Metolazone. Approved, Investigational Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Metolazone. Approved Tarenflurbil The therapeutic efficacy of Metolazone can be decreased when used in combination with Tarenflurbil. Investigational Telmisartan Metolazone may increase the hypotensive activities of Telmisartan. Approved, Investigational Temocapril The risk or severity of hypotension can be increased when Metolazone is combined with Temocapril. Experimental, Investigational Tenidap The therapeutic efficacy of Metolazone can be decreased when used in combination with Tenidap. Experimental Tenoxicam The therapeutic efficacy of Metolazone can be decreased when used in combination with Tenoxicam. Approved Tepoxalin The therapeutic efficacy of Metolazone can be decreased when used in combination with Tepoxalin. Vet Approved Terazosin The risk or severity of adverse effects can be increased when Metolazone is combined with Terazosin. Approved Terbutaline Terbutaline may increase the hypokalemic activities of Metolazone. Approved Teriflunomide The therapeutic efficacy of Metolazone can be decreased when used in combination with Teriflunomide. Approved Terlipressin Metolazone may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrahydropalmatine Metolazone may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Metolazone. Approved, Investigational, Withdrawn Theodrenaline Metolazone may increase the hypotensive activities of Theodrenaline. Investigational Thiamylal Thiamylal may increase the orthostatic hypotensive activities of Metolazone. Approved, Vet Approved Thiopental Thiopental may increase the orthostatic hypotensive activities of Metolazone. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Metolazone. Approved, Withdrawn Tiaprofenic acid The therapeutic efficacy of Metolazone can be decreased when used in combination with Tiaprofenic acid. Approved Tibolone Metolazone may increase the hypotensive activities of Tibolone. Approved, Investigational Ticrynafen Metolazone may increase the hypotensive activities of Ticrynafen. Withdrawn Tilidine The risk or severity of adverse effects can be increased when Tilidine is combined with Metolazone. Experimental Timolol Timolol may increase the hypotensive activities of Metolazone. Approved Tinoridine The therapeutic efficacy of Metolazone can be decreased when used in combination with Tinoridine. Investigational Tiotropium The serum concentration of Metolazone can be increased when it is combined with Tiotropium. Approved Tixocortol Tixocortol may increase the hypokalemic activities of Metolazone. Approved, Withdrawn Tizanidine The risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine. Approved, Investigational Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Metolazone. Approved, Investigational Tolazoline Metolazone may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Metolazone. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Metolazone. Approved, Withdrawn Tolfenamic Acid The therapeutic efficacy of Metolazone can be decreased when used in combination with Tolfenamic Acid. Approved, Investigational Tolmetin The therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin. Approved Tolonidine Metolazone may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Metolazone. Approved Tolterodine The serum concentration of Metolazone can be increased when it is combined with Tolterodine. Approved, Investigational Torasemide Torasemide may increase the hypotensive activities of Metolazone. Approved Toremifene Metolazone may increase the hypercalcemic activities of Toremifene. Approved, Investigational Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Metolazone. Approved, Investigational Trandolapril The risk or severity of hypotension can be increased when Metolazone is combined with Trandolapril. Approved Tranilast The therapeutic efficacy of Metolazone can be decreased when used in combination with Tranilast. Approved, Investigational Tranylcypromine Tranylcypromine may increase the hypotensive activities of Metolazone. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Metolazone. Approved Treprostinil Treprostinil may increase the hypotensive activities of Metolazone. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Metolazone. Approved, Investigational, Nutraceutical Triamcinolone Triamcinolone may increase the hypokalemic activities of Metolazone. Approved, Vet Approved Triamterene The risk or severity of adverse effects can be increased when Triamterene is combined with Metolazone. Approved Tribenoside The therapeutic efficacy of Metolazone can be decreased when used in combination with Tribenoside. Experimental Trichlormethiazide Metolazone may increase the hypotensive activities of Trichlormethiazide. Approved, Vet Approved Trihexyphenidyl The serum concentration of Metolazone can be increased when it is combined with Trihexyphenidyl. Approved Trimazosin Trimazosin may increase the hypotensive activities of Metolazone. Experimental Trimethaphan The serum concentration of Metolazone can be increased when it is combined with Trimethaphan. Approved, Investigational Triptolide The therapeutic efficacy of Metolazone can be decreased when used in combination with Triptolide. Investigational Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Metolazone. Investigational, Withdrawn Tropatepine The serum concentration of Metolazone can be increased when it is combined with Tropatepine. Experimental Tropicamide The serum concentration of Metolazone can be increased when it is combined with Tropicamide. Approved, Investigational Trospium The serum concentration of Metolazone can be increased when it is combined with Trospium. Approved Tubocurarine The serum concentration of Metolazone can be increased when it is combined with Tubocurarine. Approved Udenafil Udenafil may increase the antihypertensive activities of Metolazone. Approved, Investigational Ulobetasol Ulobetasol may increase the hypokalemic activities of Metolazone. Approved Umeclidinium The serum concentration of Metolazone can be increased when it is combined with Umeclidinium. Approved Unoprostone Metolazone may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Metolazone. Investigational Valdecoxib The therapeutic efficacy of Metolazone can be decreased when used in combination with Valdecoxib. Approved, Investigational, Withdrawn Valsartan Valsartan may increase the hypotensive activities of Metolazone. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Metolazone. Approved Vecuronium The serum concentration of Metolazone can be increased when it is combined with Vecuronium. Approved Venlafaxine Venlafaxine may increase the hyponatremic activities of Metolazone. Approved Verapamil The risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil. Approved Vilanterol Vilanterol may increase the hypokalemic activities of Metolazone. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Metolazone. Approved, Investigational Vincamine Metolazone may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Metolazone may increase the hypotensive activities of Vinpocetine. Investigational Vitamin D The risk or severity of hyperkalemia can be increased when Vitamin D is combined with Metolazone. Approved, Nutraceutical, Vet Approved Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Metolazone. Approved, Investigational Xipamide Metolazone may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Metolazone may increase the hypotensive activities of Xylometazoline. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Metolazone. Approved, Investigational, Vet Approved Zaltoprofen The therapeutic efficacy of Metolazone can be decreased when used in combination with Zaltoprofen. Approved, Investigational Zileuton The therapeutic efficacy of Metolazone can be decreased when used in combination with Zileuton. Approved, Investigational, Withdrawn Zimelidine Zimelidine may increase the hyponatremic activities of Metolazone. Withdrawn Zofenopril The risk or severity of hypotension can be increased when Metolazone is combined with Zofenopril. Experimental Zomepirac The therapeutic efficacy of Metolazone can be decreased when used in combination with Zomepirac. Withdrawn - Food Interactions
- Take with food to reduce gastric irritation.
References
- General References
- Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR: Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005 Aug;19(4):301-6. [PubMed:16189620]
- External Links
- Human Metabolome Database
- HMDB0014665
- KEGG Drug
- D00431
- PubChem Compound
- 4170
- PubChem Substance
- 46509058
- ChemSpider
- 4026
- BindingDB
- 25899
- ChEBI
- 64354
- ChEMBL
- CHEMBL878
- Therapeutic Targets Database
- DAP000749
- PharmGKB
- PA164781022
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Metolazone
- ATC Codes
- C03BA08 — Metolazone
- C03BA — Sulfonamides, plain
- C03B — LOW-CEILING DIURETICS, EXCL. THIAZIDES
- C03 — DIURETICS
- C — CARDIOVASCULAR SYSTEM
- C03EA — Low-ceiling diuretics and potassium-sparing agents
- C03E — DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION
- C03 — DIURETICS
- C — CARDIOVASCULAR SYSTEM
- AHFS Codes
- 40:28.24 — Thiazide-like Diuretics
- FDA label
- Download (834 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Not Available Healthy Volunteers 3 1 Recruiting Treatment Congestive Heart Failure (CHF) / Prophylaxis of cardiomyopathy 1 2 Recruiting Treatment Acute Decompensated Heart Failure (ADHF) 1 4 Completed Treatment Rapid Ventricular Response Atrial Fibrillation 1 4 Enrolling by Invitation Treatment Heart Failure, Unspecified 1 4 Terminated Treatment Acute Decompensated Heart Failure (ADHF) 1 Not Available Unknown Status Treatment Hypernatremia / Respiratory Failure / Volume Overload 1 Not Available Withdrawn Treatment Congestive Heart Failure (CHF) 2
Pharmacoeconomics
- Manufacturers
- Gd searle llc
- Mylan pharmaceuticals inc
- Roxane laboratories inc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Watson laboratories inc
- Ucb inc
- Packagers
- Amerisource Health Services Corp.
- Cardinal Health
- Caremark LLC
- Diversified Healthcare Services Inc.
- Eon Labs
- Mckesson Corp.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Prepackage Specialists
- Resource Optimization and Innovation LLC
- Sandhills Packaging Inc.
- Southwood Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- UCB Pharma
- UDL Laboratories
- Upstate Pharma LLC
- Vangard Labs Inc.
- Dosage forms
Form Route Strength Tablet Oral 10 mg/1 Tablet Oral 2.5 mg/1 Tablet Oral 5 mg/1 Tablet Oral 2.5 mg Tablet Oral 5 mg Tablet Oral 10 mg - Prices
Unit description Cost Unit Zaroxolyn 10 mg tablet 2.89USD tablet Zaroxolyn 5 mg tablet 2.75USD tablet Metolazone 10 mg tablet 1.8USD tablet Zaroxolyn 2.5 mg tablet 1.74USD tablet Metolazone 5 mg tablet 1.51USD tablet Metolazone 2.5 mg tablet 1.37USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 256 °C PhysProp water solubility 60.3 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 2.5 Not Available logS -3.78 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.0407 mg/mL ALOGPS logP 3.21 ALOGPS logP 2.94 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 9.54 ChemAxon pKa (Strongest Basic) -1.6 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 92.5 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 94.59 m3·mol-1 ChemAxon Polarizability 36.38 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9972 Blood Brain Barrier + 0.5944 Caco-2 permeable - 0.8957 P-glycoprotein substrate Non-substrate 0.7578 P-glycoprotein inhibitor I Non-inhibitor 0.8113 P-glycoprotein inhibitor II Non-inhibitor 0.5921 Renal organic cation transporter Non-inhibitor 0.9223 CYP450 2C9 substrate Non-substrate 0.6466 CYP450 2D6 substrate Non-substrate 0.8279 CYP450 3A4 substrate Non-substrate 0.579 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Non-inhibitor 0.923 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.831 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5788 Ames test Non AMES toxic 0.8234 Carcinogenicity Non-carcinogens 0.7193 Biodegradation Not ready biodegradable 0.9961 Rat acute toxicity 1.8955 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9922 hERG inhibition (predictor II) Non-inhibitor 0.8735
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0aor-1494000000-aae5f0a5c86e9d0828e2 MS/MS Spectrum - , positive LC-MS/MS splash10-0bvi-2960000000-1eed022b28a6bb140f60
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazanaphthalenes
- Sub Class
- Benzodiazines
- Direct Parent
- Quinazolines
- Alternative Parents
- Toluenes / Secondary alkylarylamines / Organosulfonamides / Aryl chlorides / Vinylogous amides / Tertiary carboxylic acid amides / Aminosulfonyl compounds / Lactams / Amino acids and derivatives / Azacyclic compounds show 5 more
- Substituents
- Quinazoline / Secondary aliphatic/aromatic amine / Toluene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Vinylogous amide show 22 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- sulfonamide, organochlorine compound, quinazolines (CHEBI:64354)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transporter activity
- Specific Function
- Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
- Gene Name
- SLC12A3
- Uniprot ID
- P55017
- Uniprot Name
- Solute carrier family 12 member 3
- Molecular Weight
- 113138.04 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:00